Dephosphorylation of p53 at Ser20 after cellular exposure to low levels of non-ionizing radiation

被引:33
作者
Craig, AL
Blaydes, JP
Burch, LR
Thompson, AM
Hupp, TR [1 ]
机构
[1] Univ Dundee, Dundee Canc Res Inst, Dept Mol & Cellular Pathol, Dundee DD1 9SY, Scotland
[2] Univ Dundee, Dundee Canc Res Inst, Dept Mol Oncol, Dundee DD1 9SY, Scotland
[3] Univ Dundee, Dundee Canc Res Inst, Dept Surg, Dundee DD1 9SY, Scotland
基金
英国医学研究理事会;
关键词
p53; transcription; kinase; radiation; phosphorylation;
D O I
10.1038/sj.onc.1203085
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Induction of the transactivation function of p53 after cellular irradiation was studied under conditions in which upstream signaling events modulating p53 activation were uncoupled from those regulating stabilization. This investigation prompted the discovery of a novel radiation-responsive kinase pathway targeting Ser20 that results in the masking of the DO-1 epitope in undamaged cells. Unmasking of the DO-1 epitope via dephosphorylation occurs in response to low doses of nonionizing radiation. Our data show that phosphorylation at Ser20 reduces binding of the mdm2 protein, suggesting that a function of the Ser20-kinase pathway may be to produce a stable pool of inactive p53 in undamaged cells which can be readily activated after cellular injury. Phospho-specific monoclonal antibodies were used to determine whether the Ser20 signaling pathway is coupled to the Ser15 and Ser392 radiation-responsive kinase pathways. These results demonstrated that: (1) dephosphorylation at Ser20 is co-ordinated with an increased steady-state phosphorylation at Ser392 after irradiation, without p53 protein stabilization, and (2) stabilization of p53 protein can occur without Ser15 phosphorylation at higher doses of radiation. These data show that the Ser20 and Ser392 phosphorylation sites are both targeted by an integrated network of signaling pathways which is acutely sensitive to radiation injury.
引用
收藏
页码:6305 / 6312
页数:8
相关论文
共 36 条
[1]  
[Anonymous], 1993, PROTEIN PHOSPHORYLAT
[2]   p53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancer [J].
Berns, EMJJ ;
Klijn, JGM ;
van Putten, WLJ ;
de Witte, HH ;
Look, MP ;
Gelder, MEM ;
Willman, K ;
Portengen, H ;
Benraad, TJ ;
Foekens, JA .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (01) :121-127
[3]   Tolerance of high levels of wild-type p53 in transformed epithelial cells dependent on auto-regulation by mdm-2 [J].
Blaydes, JP ;
Gire, V ;
Rowson, JM ;
WynfordThomas, D .
ONCOGENE, 1997, 14 (15) :1859-1868
[4]   DNA damage triggers DRB-resistant phosphorylation of human p53 at the CK2 site [J].
Blaydes, JP ;
Hupp, TR .
ONCOGENE, 1998, 17 (08) :1045-1052
[5]  
BOND J, 1999, IN PRESS ONCOGENE
[6]   Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo [J].
Bottger, A ;
Bottger, V ;
Sparks, A ;
Liu, WL ;
Howard, SF ;
Lane, DP .
CURRENT BIOLOGY, 1997, 7 (11) :860-869
[7]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[8]   p53 is a general repressor of RNA polymerase III transcription [J].
Cairns, CA ;
White, RJ .
EMBO JOURNAL, 1998, 17 (11) :3112-3123
[9]  
Chesnokov I, 1996, MOL CELL BIOL, V16, P7084
[10]  
DOVER R, 1994, J CELL SCI, V107, P1181